Orano Med

Orano Med is at the forefront of developing a new generation of targeted cancer therapies, leveraging the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope known for its significant cytotoxic capabilities. With a dedicated team of 230 professionals across France and the United States, Orano Med operates three preclinical laboratories focused on advancing alpha therapies. Their state-of-the-art industrial platform is designed for the production of 212Pb, ensuring a robust supply for ongoing research and clinical applications.

Currently, the company is conducting two clinical trials, reflecting its commitment to translating innovative research into real-world treatments. Orano Med holds 18 patent families and is positioned to capitalize on the rapidly growing market for targeted internal radiotherapies, which is expected to grow at over 30% annually. With its focus on precision medicine, Orano Med aims to make targeted alpha therapy a standard option in the fight against cancer, paving the way for more effective treatment solutions